EU HTA Regulation (EU) 2021/2282: joint clinical assessments

European Union, regulation. Regulation (EU) 2021/2282 on health technology assessment of 15 December 2021 applies from 12 January 2025, first to medicines for cancer and advanced therapy medicinal products, then to orphan medicines from January 2028 and all new medicines from January 2030. Primary text: EUR-Lex; the Commission's HTA pages carry the implementing acts and the Coordination Group's methods.

What it does: when a medicine enters the centralised authorisation procedure, the Member State Coordination Group on HTA scopes the questions each country needs answered (populations, comparators, outcomes, the 'PICO' scope) and produces a joint clinical assessment report on relative effectiveness and its uncertainty, published shortly after the Commission's authorisation decision. Member states must give it 'due consideration' but keep national responsibility for appraisal, pricing and reimbursement. Joint scientific consultations let developers ask for advice on trial design early, and horizon scanning identifies coming technologies.

Why it matters for oncology and the arguments: cancer medicines are the first cohort precisely because they are where national assessments diverged most and where the gap between approval and reimbursement is longest. Industry fears the consolidated PICO scopes will demand many comparisons that a pivotal trial could not have anticipated, and that a critical joint report will follow a product into every negotiation; payers see one rigorous assessment instead of repeated work; patient groups want faster, more even access across richer and poorer member states. The first oncology joint assessments began in 2025 and their timing relative to national decisions is the metric to watch.